RCAG
HAE icon

Rehmann Capital Advisory Group’s Haemonetics HAE Stock Holding History

Rehmann Capital Advisory Group’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-2
Closed -$200 – 2108
2018
Q4 		$200 Hold
2
– – ﹤0.01% 1793
2018
Q3 		$229 Sell
2
-76
-97% -$7.87K ﹤0.01% 2095
2018
Q2 		$7K Hold
78
– – ﹤0.01% 1461
2018
Q1 		$6K Buy
+78
New +$5.35K ﹤0.01% 1464

Other funds holding HAE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Rehmann Capital Advisory Group's HAE Position: Q1 2019 in Review

Rehmann Capital Advisory Group sold out of Haemonetics (HAE) in Q1 2019, closing a stake of 2 shares — an estimated $200 sold.

Rehmann Capital Advisory Group first reported a position in HAE in Q1 2018 and held it in 4 quarters. The position peaked at $7K in Q2 2018. 260 funds tracked by Wall St. Rank hold HAE as of Q1 2019.

  • Rehmann Capital Advisory Group reported no remaining Haemonetics position as of Q1 2019 after selling out during the quarter.
  • Rehmann Capital Advisory Group sold 2 Haemonetics shares in Q1 2019, an estimated $200.
  • Rehmann Capital Advisory Group first reported a position in Haemonetics in Q1 2018 and held it in 4 quarters.
  • Rehmann Capital Advisory Group's Haemonetics position peaked at $7K in Q2 2018.
  • 260 funds tracked by Wall St. Rank held Haemonetics as of Q1 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2019, filed 22 May 2019.